drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody immunotherapy (biological drug)
drug_description
Glycoengineered humanized type II anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct non-complement cell death, aiming to reduce autoantibody production and immune complex formation; administered 1 g IV on day 1 and day 15, repeated at month 6.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
obinutuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Glycoengineered humanized type II anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct non-complement-mediated cell death, reducing autoantibody production and immune complex formation.
drug_name
Obinutuzumab (Gazyva)
nct_id_drug_ref
NCT06295770